MedWatch

Positive data on new antidepressant from Lundbeck

Lundbeck have reported positive results from a phase III trial with a new antidepressant candidate from the Danish company.

Foto: PR lundbeck

Lundbeck’s candidate drug, the antidepressant Brintellix, performs better than a possible rival drug, Valdoxan (agomelatin), in patients with major depression and inadequate response to SSRI or SNRI therapy, results from a recently concluded phase III trial with the two drugs indicate, according to a statement released on Monday.

"Patients with inadequate response to current SSRI or SNRI therapies represent a large proportion of patients suffering from major depression. Only a few years ago, the landmark STAR*D study1 confirmed a significant unmet medical need as only half of patients responded to their first-line treatment, which was an SSRI. First-line treatments in clinical practice are typically SSRIs or SNRIs," says Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier